140 related articles for article (PubMed ID: 20116624)
1. [Safety and tolerability of etravirine].
Portilla J
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():21-6. PubMed ID: 20116624
[TBL] [Abstract][Full Text] [Related]
2. [Role of etravirine in combination antiretroviral therapy].
Domingo P
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
[TBL] [Abstract][Full Text] [Related]
3. [Etravirine in first-line therapy].
Garcés PA; Tena EV
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():12-20. PubMed ID: 20116623
[TBL] [Abstract][Full Text] [Related]
4. [Etravirine in highly treatment-experienced patients].
Palter DP; Corbera EF; Tiraboschi JM
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():6-11. PubMed ID: 20116622
[TBL] [Abstract][Full Text] [Related]
5. [Etravirine in special populations].
Santos Gil Ide L
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():40-5. PubMed ID: 20116627
[TBL] [Abstract][Full Text] [Related]
6. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
Schiller DS; Youssef-Bessler M
Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
[TBL] [Abstract][Full Text] [Related]
7. [Introduction. Etravirine: a new standard of potency and safety among non-nucleoside analogues].
Domingo P
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():1. PubMed ID: 20116620
[No Abstract] [Full Text] [Related]
8. [Etravirine: genetic barrier and resistance development].
Llibre JM; Santos JR; Clotet B
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():32-9. PubMed ID: 20116626
[TBL] [Abstract][Full Text] [Related]
9. Etravirine.
Deeks ED; Keating GM
Drugs; 2008; 68(16):2357-72. PubMed ID: 18973398
[TBL] [Abstract][Full Text] [Related]
10. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.
Jaworsky D; Thompson C; Yudin MH; Bitnun A; Brophy J; Samson L; Antoniou T; Loutfy MR
Antivir Ther; 2010; 15(4):677-80. PubMed ID: 20587860
[TBL] [Abstract][Full Text] [Related]
11. A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s).
Ruane P; Alas B; Ryan R; Perniciaro A; Witek J
AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1215-9. PubMed ID: 21083412
[TBL] [Abstract][Full Text] [Related]
12. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience.
Gazzola L; Cicconi P; Ripamonti D; Di Filippo E; Gustinetti G; Di Biagio A; Marchetti G; Bini T; d'Arminio Monforte A
HIV Clin Trials; 2014; 15(4):140-50. PubMed ID: 25143023
[TBL] [Abstract][Full Text] [Related]
14. Etravirine.
Knoll BM; Vento S; Temesgen Z
Drugs Today (Barc); 2008 Jan; 44(1):23-33. PubMed ID: 18301801
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.
Montaner J; Yeni P; Clumeck NN; Fätkenheuer G; Gatell J; Hay P; Seminari E; Peeters MP; Schöller-Gyüre M; Simonts M; Woodfall B;
Clin Infect Dis; 2008 Oct; 47(7):969-78. PubMed ID: 18764771
[TBL] [Abstract][Full Text] [Related]
16. Etravirine in the treatment of HIV-1: a clinical overview for healthcare professionals.
Yeni P; Mills A; Peeters M; Vingerhoets J; Kakuda TN; De Smedt G; Woodfall B
Curr HIV Res; 2010 Oct; 8(7):564-76. PubMed ID: 20946097
[TBL] [Abstract][Full Text] [Related]
17. Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra study.
Schneider L; Ktorza N; Fourati S; Assoumou L; Courbon E; Caby F; Blanc C; Tindel M; Agher R; Marcelin AG; Calvez V; Peytavin G; Katlama C
HIV Clin Trials; 2012; 13(5):284-8. PubMed ID: 23134629
[TBL] [Abstract][Full Text] [Related]
18. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.
Johnson LB; Saravolatz LD
Clin Infect Dis; 2009 Apr; 48(8):1123-8. PubMed ID: 19275497
[TBL] [Abstract][Full Text] [Related]
19. Etravirine: new drug. Multidrug-resistant HIV: another option.
Prescrire Int; 2009 Jun; 18(101):102-3. PubMed ID: 19637414
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
Katlama C; Haubrich R; Lalezari J; Lazzarin A; Madruga JV; Molina JM; Schechter M; Peeters M; Picchio G; Vingerhoets J; Woodfall B; De Smedt G;
AIDS; 2009 Nov; 23(17):2289-300. PubMed ID: 19710593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]